Source BioScience

SourceBioscience, a GLP/GCP accredited Biotechnology company with an expertise in genomics and molecular biology/tissue pathology is offering genotyping services for patient stratification to support global clinical trials.

Mutation Testing Services
SourceBioscience provides ‘state of the art’ genomics testing and a ‘one stop shop’ for its clinical trial customers.  The company  has expanded its operating facilities, and now has 5 laboratories in Cambridge, Oxford, Nottingham, London and Dublin,  providing gene sequencing and genotyping for mutation analysis and patient stratification as well as expert pathology review and specialist tissue pathology services.. It is the biggest provider in the UK of next generation sequencing services with CsPro accreditation for excellence.
Mutation analysis tests include  K-ras, B-raf,  & EGFR using rtPCR technology, as well as a newly validated NRAS test and  PI3K by pyrosequencing.  The company can offer tailor made services to companies looking to develop and validate biomarkers for companion diagnostic use.
Source BioScience is also a provider of  drug metabolism assays such as CYPs, and kinases using ABI and Affy Chip technology. It also provides CYP2D testing using the Roche amplichip.
SourceBioscience is a global company providing worldwide support for pre-clinical and clinical trial testing in all major therapeutic areas with an expertise in oncology.  Using its new genomics facilities, the company can  offer support for development programs in early discovery for new drugs and disease targets, through to pre-clinical and clinical trial testing.  Dedicated project teams are used to streamline and facilitate the process for studies including submission  to the FDA.

Specialist Central Reference Laboratory Technologies
SourceBioscience has made considerable investment in technologies to further support  diagnostic, predictive and prognostic profiling.  A comprehensive testing service is provided for HER2 & EGFR including quantitative IHC for protein expression and FISH for assessing gene copy number and/or amplification. FISH analysis of the Topoisomerase 2a gene, as a means of assessing likely response to anthracycline agents is also offered to provide data to enhance treatment options for the patient.
Source BioScinece is a european reference laboratory for Circulating tumour cell (CTC) and Circulating Endothelial cells (CEC). Enumeration of these cells is provided as well as genomic extraction from circulating cells and ECDs. Our next generation sequencing capabilities can be used to 'muliplex' mutation tests which is very useful for small samples such as FNAs, as well as looking at abberant tumour signals.  IHC/FISH testing is offered to determine protein expression and increased copy numbers.

Facilitation of Patient Stratification
SourceBioscience offers mutation testing to provide data on whether a patient will respond to a drug before being entered into a clinical trial, as well as tests to measure how well a patient is responding to drug and hormone treatments. These tests are provided to support clinical and market access trials, or on a sample per sample basis to the private pathology market.